SHIELD-T1D trial to preserve beta-cell function with Shingrix and Semaglutide in Type 1 Diabetes.
Background
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic beta cells, leading to absolute insulin deficiency. Preserving residual beta-cell function, indicated by detectable C-peptide, is crucial for improved glycemic control, reduced hypoglycemia, and fewer long-term vascular complications. Current therapies primarily manage symptoms, leaving a significant gap in strategies to halt or reverse beta-cell loss. This trial explores a novel combinatorial approach targeting both immune dysregulation and beta-cell cytoprotection, aiming to leverage the immunomodulatory effects of a vaccine adjuvant and the metabolic benefits of a GLP-1 receptor agonist.
Study Design
The SHIELD-T1D study is designed as a randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. It aims to enroll 240 adults (18-50 years) diagnosed with T1D within 100 days of diagnosis, with confirmed residual beta-cell function (stimulated C-peptide ≥0.2 nmol/L). Participants are randomized 1:1:1:1 into one of four treatment arms: Shingrix alone, Semaglutide alone, a Shingrix + Semaglutide combination, or a dual placebo arm. The primary endpoint for this 12-month study is the change in 2-hour stimulated C-peptide AUC during a Mixed Meal Tolerance Test (MMTT) from baseline to 12 months, assessing the preservation of endogenous insulin secretion.
Why It Matters
If successful, this trial could establish a groundbreaking strategy for T1D beta-cell preservation by combining immunomodulation with metabolic support. The AS01B adjuvant system in Shingrix aims to promote regulatory T-cell (Treg) expansion and shift the immunological milieu toward tolerance, while GLP-1 receptor agonism from Semaglutide offers direct beta-cell cytoprotection, reduces glucotoxicity, and may suppress autoimmune cytokine signaling. This dual approach could significantly improve long-term outcomes for individuals with recent-onset T1D, potentially reducing insulin dependence, mitigating the burden of hypoglycemia, and preventing severe vascular complications. This represents a critical step towards a disease-modifying therapy beyond current symptomatic management, offering a new paradigm for T1D intervention.